This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Multiple myeloma
  • /
  • Ixazomib significantly prolongs progression-free s...
Journal

Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients.

Read time: 1 mins
Published:20th Oct 2017
Author: Avet-Loiseau H, Bahlis NJ, Chng WJ, Masszi T, Viterbo L, Pour L et al.
Source: Blood
Availability: Pay for access, or by subscription
Ref.:Blood. 2017. pii: blood-2017-06-791228.
DOI:10.1182/blood-2017-06-791228
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest